Q-omics provides the consensus-scored B3GNT8 profile across patient tissues and cancer cell-line models. B3GNT8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, B3GNT8 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, B3GNT8 RNA expression shows 14,514 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where B3GNT8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GNT8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GNT8 survival associations across molecular data types. B3GNT8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GNT8 RNA expression–survival associations across cancer types. High B3GNT8 expression shows unfavorable associations in KIRP, KIRC and OV, but favorable associations in LUAD, ACC and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for B3GNT8 RNA expression.
This table summarizes B3GNT8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for B3GNT8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GNT8 shows lower tumor expression in COAD, KIRC, LUAD and LUSC and higher tumor expression in THCA and CHOL. The THCA box plot shows higher B3GNT8 RNA expression in tumor versus normal tissue (log2 FC = +1.638, t-test p < 0.001).
This table shows molecular features associated with B3GNT8 in patient tissues and cancer cell lines. In patient samples, B3GNT8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GNT8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
